Jonathan Synett

Avvinity Therapeutics Ltd. develops novel immuno-therapeutics. The British company was founded in 2016 by Mike Westby, Jonathan David Moore. The CEO is Nick Staples.

Avvinity Therapeutics Ltd. develops novel immuno-therapeutics. The British company was founded in 2016 by Mike Westby, Jonathan David Moore. The CEO is Nick Staples.

Viramal Ltd. operates as a biotechnology company and develops drugs for male and female sexual and hormone problems. The company was founded by Oliver Bates and Finn Larsen in 2013 and is headquartered in London, the United Kingdom.

Viramal Ltd. operates as a biotechnology company and develops drugs for male and female sexual and hormone problems. The company was founded by Oliver Bates and Finn Larsen in 2013 and is headquartered in London, the United Kingdom.

Viramal Ltd. operates as a biotechnology company and develops drugs for male and female sexual and hormone problems. The company was founded by Oliver Bates and Finn Larsen in 2013 and is headquartered in London, the United Kingdom.

Viramal Ltd. operates as a biotechnology company and develops drugs for male and female sexual and hormone problems. The company was founded by Oliver Bates and Finn Larsen in 2013 and is headquartered in London, the United Kingdom.

Alert Technology Ltd. engages in the manufacture of electronic measuring and esting equipment. The company was founded on August 29, 2005 and is headquartered in Devon, the United Kingdom.

Alert Technology Ltd. engages in the manufacture of electronic measuring and esting equipment. The company was founded on August 29, 2005 and is headquartered in Devon, the United Kingdom.

Viramal Ltd. operates as a biotechnology company and develops drugs for male and female sexual and hormone problems. The company was founded by Oliver Bates and Finn Larsen in 2013 and is headquartered in London, the United Kingdom.

Azadyne Ltd. is an Irish preclinical biotech company that has identified a new target within the body and a previously undrugged pathway to treat autoimmune diseases. Azadyne is based in Dublin2, IE. The company is able to selectively control natural regulatory pathways to modify specific pathogenic immune populations. The company's groundbreaking work in RNA modification has been supported by investment syndicates led by NCL. The company was founded in 2019 by Jason Rutt, Vincent Kelly, Stephen Connon, and Mike Southern to commercialize the pioneering work on the QTRT or TGT pathway carried out in Profs Kelly, Connon & Southerns labs at Trinity College Dublin.

Azadyne Ltd. is an Irish preclinical biotech company that has identified a new target within the body and a previously undrugged pathway to treat autoimmune diseases. Azadyne is based in Dublin2, IE. The company is able to selectively control natural regulatory pathways to modify specific pathogenic immune populations. The company's groundbreaking work in RNA modification has been supported by investment syndicates led by NCL. The company was founded in 2019 by Jason Rutt, Vincent Kelly, Stephen Connon, and Mike Southern to commercialize the pioneering work on the QTRT or TGT pathway carried out in Profs Kelly, Connon & Southerns labs at Trinity College Dublin.

Azadyne Ltd. is an Irish preclinical biotech company that has identified a new target within the body and a previously undrugged pathway to treat autoimmune diseases. Azadyne is based in Dublin2, IE. The company is able to selectively control natural regulatory pathways to modify specific pathogenic immune populations. The company's groundbreaking work in RNA modification has been supported by investment syndicates led by NCL. The company was founded in 2019 by Jason Rutt, Vincent Kelly, Stephen Connon, and Mike Southern to commercialize the pioneering work on the QTRT or TGT pathway carried out in Profs Kelly, Connon & Southerns labs at Trinity College Dublin.

Avvinity Therapeutics Ltd. develops novel immuno-therapeutics. The British company was founded in 2016 by Mike Westby, Jonathan David Moore. The CEO is Nick Staples.

Avvinity Therapeutics Ltd. develops novel immuno-therapeutics. The British company was founded in 2016 by Mike Westby, Jonathan David Moore. The CEO is Nick Staples.

Azadyne Ltd. is an Irish preclinical biotech company that has identified a new target within the body and a previously undrugged pathway to treat autoimmune diseases. Azadyne is based in Dublin2, IE. The company is able to selectively control natural regulatory pathways to modify specific pathogenic immune populations. The company's groundbreaking work in RNA modification has been supported by investment syndicates led by NCL. The company was founded in 2019 by Jason Rutt, Vincent Kelly, Stephen Connon, and Mike Southern to commercialize the pioneering work on the QTRT or TGT pathway carried out in Profs Kelly, Connon & Southerns labs at Trinity College Dublin.

NCL Technology Ventures Ltd. (NCL Technology Ventures) is an venture capital firm founded in 2010 by Jerry Biggs. The firm is headquartered in London, United Kingdom.

NCL Technology Ventures Ltd. (NCL Technology Ventures) is an venture capital firm founded in 2010 by Jerry Biggs. The firm is headquartered in London, United Kingdom.

Avvinity Therapeutics Ltd. develops novel immuno-therapeutics. The British company was founded in 2016 by Mike Westby, Jonathan David Moore. The CEO is Nick Staples.